Comparison of gemcitabine monotherapy with gemcitabine and cisplatin combination in metastatic pancreatic cancer: a retrospective analysis

Ergun Y., Ozdemir N. Y. , Guner E. K. , Esin E., ŞENDUR M. A. N. , Koksoy E. B. , ...Daha Fazla

JOURNAL OF BUON, cilt.23, 2018 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 23
  • Basım Tarihi: 2018
  • Dergi Adı: JOURNAL OF BUON


Purpose: Gemcitabine is among the standard first-line agents for the treatment of metastatic pancreatic cancer. However, as the median survival with gemcitabine monotherapy is 6 months, different combinations are being studied for better, prolonged survival. In this multicenter study, we aimed to compare the results of gemcitabine monotherapy with those of gemcitabine and cisplatin combination therapy as first-line treatments for metastatic pancreatic cancer.